Influenza News and Research

Latest Influenza News and Research

Orally effective FluCide anti-influenza drug candidate

NanoViricides, Inc. announced today that an anti-influenza drug candidate under its FluCide program is effective when given orally. The Company has received information that a FluCide drug candidate designed for oral administration has shown very strong efficacy in corresponding animal studies.

13 Aug 2012

BioDiem granted European patent for antimicrobial drug

Australian vaccine development company BioDiem Ltd (ASX: BDM) announced today the successful granting of a key European patent for its synthetic antimicrobial compound BDM-I. BDM-I is a novel compound active against a range of pathogenic micro-organisms including bacteria, fungi and protozoa. The patent provides protection around BDM-I as a treatment for vulvovaginitis, a general term for inflammation of the vulva or vagina.

7 Aug 2012

Creating new non-influenza vaccines: an interview with Julie Phillips, CEO of BioDiem

BioDiem recently signed a collaborative agreement with The Royal Melbourne Institute of Technology (RMIT) for the development of non-influenza vaccines using BioDiem’s proprietary live attenuated influenza virus (LAIV) technology.

7 Aug 2012

Drug molecules designed for influenza may be adapted to treat other viruses

St. Jude Children's Research Hospital study shows how compounds blocking an enzyme universal to all influenza viruses may allow development of new antiviral drugs that also avoid the problem of drug resistance

3 Aug 2012

GSK begins shipping the first lots of 2012-2013 seasonal influenza vaccines

GlaxoSmithKline announced today it has begun shipping the first lots of 2012-2013 FluLaval (Influenza virus vaccine) and Fluarix (Influenza Virus Vaccine) to CDC distribution centers and U.S. healthcare providers.

1 Aug 2012

Australia's top medical researchers for 2012 announced

Finalists for one of Australia’s longest running and most prestigious awards for medical research were announced today. This year’s winner will join a list of alumni winners that includes many of the country’s most respected scientists.

31 Jul 2012

Progress with GSK in advancing VaxiRNA technology earns Alnylam $3.2M milestone payment

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has earned a development milestone payment from GlaxoSmithKline, totaling $3.2 million. The milestone payment is related to progress in the companies' collaboration on the use of VaxiRNA technology for the production of GSK influenza vaccine.

30 Jul 2012

Promising implications for improving cellular immunotherapy for treatment of cancer

New research from the Trudeau Institute laboratory of Dr. Edward L. Pearce (Washington University) has promising implications for improving a treatment for cancer known as cellular immunotherapy. The findings were just published in the The Journal of Immunology.

30 Jul 2012

UTMB researchers receives NIH grant to develop engineered lung tissue for biomedical studies

University of Texas Medical Branch at Galveston researchers have been awarded a two-year, $1.25 million National Institutes of Health grant to develop a method of custom-growing human lung tissue to make a three-dimensional model for biomedical studies.

30 Jul 2012

Tips to prevent illness in crowds

Massive crowds from around the globe will mingle in London during the Olympics, and that means a world-class array of germs will mix with them. Mayo Clinic infectious diseases expert Gregory Poland, M.D., offers several tips for avoiding illness when you are around lots of people, whether at the Olympics, a professional football game, convention, arena concert or other major event.

26 Jul 2012

Rutgers cell biologist to receive Presidential Early Career Award for Scientists and Engineers

Fewer than 100 researchers nationwide are chosen each year to receive the Presidential Early Career Award for Scientists and Engineers (PECASE), and this year Dr. Nihal Altan-Bonnet is one of the 96 to receive this honor.

25 Jul 2012

Researchers discover bats as reservoir of infections

Measles, mumps, pneumonia, influenza and encephalitis in man, Carré's disease in dogs, Ovine Rinderpest (PPR)… all of these diseases are caused by viruses from the same family: Paramyxoviridae. A vast international study, carried out in collaboration with IRD researchers and published in Nature communications has led to the discovery of more than 60 new species of these dangerous infectious agents, almost double the number previously recorded. This family of highly diverse pathogens affects all animals, from canines to fowl, cattle and humans.

25 Jul 2012

Favorable results from BioCryst’s ulodesine plus allopurinol Phase 2b trial on gout

BioCryst Pharmaceuticals, Inc. announced favorable 52-week safety results and sustained efficacy from the extension phase of its randomized Phase 2b trial of ulodesine (BCX4208) added to allopurinol in patients with gout who had failed to reach the serum uric acid (sUA) therapeutic goal of <6 mg/dL on allopurinol alone, as well as positive Phase 2 safety results in patients with mild to moderate renal impairment.

25 Jul 2012

BioDiem presents positive findings of their eye disease drug at international conference

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced positive results from formal studies of its BDM-E eye disease drug, presented over 21 – 22 July at the International Society for Eye Research (ISER) meeting in Berlin, Germany. The ISER convenes leading researchers and clinicians in the area of eye disease.

22 Jul 2012

Exposure to high-intensity vibrations increases risk of Parkinson's

Severe influenza doubles the odds that a person will develop Parkinson's disease later in life, according to University of British Columbia researchers.

21 Jul 2012

New CHAIT initiative on development of novel immunological therapeutic interventions

The CHAIT initiative is a public-private partnership focusing on the development of novel immunological therapeutic interventions to achieve a 'functional HIV cure' with the ultimate goal of HIV eradication.

21 Jul 2012

BioDiem signs agreement with RMIT to create new non-influenza vaccines

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced that BioDiem has signed an agreement with The Royal Melbourne Institute of Technology (RMIT) regarding a research program that will investigate the use of BioDiem’s live attenuated influenza virus (LAIV) to create new non-influenza vaccines. Developing the potential of the LAIV technology for new indications is an important part of BioDiem’s strategy, and this research is part of the work towards that goal.

19 Jul 2012

Abscisic acid has anti-inflammatory effects in the lungs and gut

Building on previous work with the botanical abscisic acida, researchers in the Nutritional Immunology and Molecular Medicine Laboratory (NIMML) have discovered that abscisic acid has anti-inflammatory effects in the lungs as well as in the gut.

19 Jul 2012

College-age children also need immunizations, says UMDNJ professor

Most parents take their young children regularly for immunization shots that protect against polio, diphtheria, measles, mumps and other diseases. But many do not consider that their college-age children also need immunizations.

14 Jul 2012

Health risks associated with H1N1 vaccine investigated

Results from two studies published in JAMA show that the H1N1 vaccination is associated with a small, but significant, increase in risk for Guillain-Barré syndrome in adults, but does not increase the risk for birth defects or problems when given to pregnant women.

11 Jul 2012

Influenza News and Research

Latest Influenza News and Research

Orally effective FluCide anti-influenza drug candidate

BioDiem granted European patent for antimicrobial drug

Creating new non-influenza vaccines: an interview with Julie Phillips, CEO of BioDiem

Drug molecules designed for influenza may be adapted to treat other viruses

GSK begins shipping the first lots of 2012-2013 seasonal influenza vaccines

Australia's top medical researchers for 2012 announced

Progress with GSK in advancing VaxiRNA technology earns Alnylam $3.2M milestone payment

Promising implications for improving cellular immunotherapy for treatment of cancer

UTMB researchers receives NIH grant to develop engineered lung tissue for biomedical studies

Tips to prevent illness in crowds

Rutgers cell biologist to receive Presidential Early Career Award for Scientists and Engineers

Researchers discover bats as reservoir of infections

Favorable results from BioCryst’s ulodesine plus allopurinol Phase 2b trial on gout

BioDiem presents positive findings of their eye disease drug at international conference

Exposure to high-intensity vibrations increases risk of Parkinson's

New CHAIT initiative on development of novel immunological therapeutic interventions

BioDiem signs agreement with RMIT to create new non-influenza vaccines

Abscisic acid has anti-inflammatory effects in the lungs and gut

College-age children also need immunizations, says UMDNJ professor

Health risks associated with H1N1 vaccine investigated

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Influenza News and Research

Latest Influenza News and Research

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Newsletters you may be interested in